Details of Drug-Drug Interaction
| Drug General Information (ID: DDIJKOVS5F) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Isosorbide mononitrate | Drug Info | Riociguat | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Vasodilator Agents | Vasodilator Agents | |||||||
| Structure | |||||||||
| Mechanism of Isosorbide mononitrate-Riociguat Interaction (Severity Level: Major) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Additive hypotensive effects Click to Show/Hide Mechanism Graph | |||||||||
![]() |
|||||||||
| Drug Name | Isosorbide mononitrate | Riociguat | |||||||
| Mechanism |
Hypotensive effects Guanylate cyclase Agonist |
Hypotensive effects Soluble guanylyl cyclase Agonist |
|||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Guanylate cyclase soluble | Structure Sequence | |||||||
| Protein Family | Adenylyl cyclase class-4/guanylyl cyclase family | ||||||||
| Protein Function |
There are two types of guanylate cyclases: soluble forms and membrane-associated receptor forms. Activated by nitric oxide in the presence of magnesium or manganese ions.
Click to Show/Hide
|
||||||||
| Key Mechanism Factor 2 | |||||||||
| Factor Name | Guanylate cyclase soluble | Structure Sequence | |||||||
| Protein Family | Adenylyl cyclase class-4/guanylyl cyclase family | ||||||||
| Protein Function |
Mediates responses to nitric oxide (NO) by catalyzing the biosynthesis of the signaling molecule cGMP.
Click to Show/Hide
|
||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Concomitant use of riociguat with organic nitrates (e.g., nitroglycerin) or nitric oxide donors (e.g., amyl nitrite) in any form is considered contraindicated. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT. | ||||||||||||||||||

